How Can We Engineer CAR T Cells to Overcome Resistance?

Maya Glover,1 Stephanie Avraamides,2 John Maher1– 4 1Leucid Bio Ltd., Guy’s Hospital, London, SE1 9RT, UK; 2King’s College London, School of Cancer and Pharmaceutical Sciences, Guy’s Hospital, London, SE1 9RT, UK; 3Department of Clinical Immunology and Allergy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Glover M, Avraamides S, Maher J
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/83cff87a5797459291983d07914ea971
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!